Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

140.70
-6.7900-4.60%
Post-market: 141.270.5700+0.41%19:30 EDT
Volume:298.91K
Turnover:42.15M
Market Cap:4.97B
PE:-7.84
High:146.77
Open:146.77
Low:138.82
Close:147.49
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:0.72
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.47
PE(LYR):-5.57

Loading ...

Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL

TIPRANKS
·
Jun 10

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

GlobeNewswire
·
Jun 10

Avis Budget Group Is Maintained at Underweight by JP Morgan

Dow Jones
·
Jun 09

What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders

Simply Wall St.
·
Jun 09

Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance

TIPRANKS
·
Jun 09

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

GlobeNewswire
·
Jun 09

Avis Budget price target raised to $155 from $140 at JPMorgan

TIPRANKS
·
Jun 09

Avis Budget Group Inc : JP Morgan Raises Target Price to $155 From $140

THOMSON REUTERS
·
Jun 09

Avis Budget Group Inc. : Barclays Raises to Equal-Weight From Underweight

THOMSON REUTERS
·
Jun 09

U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers

Reuters
·
Jun 09

Imugene Wins FDA Fast Track for Off-the-Shelf CAR T in CLL/SLL and MZL

TIPRANKS
·
Jun 09

Avis Budget Shares Rise After Upgrade From Barclays

MT Newswires Live
·
Jun 09

Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says

MT Newswires Live
·
Jun 08

Avis Budget Group Raised to Equal-Weight From Underweight by Barclays

Dow Jones
·
Jun 08

Movement Alert|Avis Budget Group Rises 5.21% in Regular Trading, Upgraded by Barclays to Equal Weight

Market Focus
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Barclays Upgrades Avis Budget Group to Equalweight From Underweight, Adjusts PT to $160 From $140

MT Newswires Live
·
Jun 08

A Look At Cencora (COR) Valuation After 2026 Guidance Update And New CAR T Distribution Deal

Simply Wall St.
·
Jun 08

What Is the Impact of Rupiah Weakening on Banks?

Tempo
·
Jun 05

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline

TIPRANKS
·
Jun 05